Hot topics | Coronavirus pandemic

Addex Therapeutics Ltd (ADXN) July 20, 2021 Stock Price, Analysis & Forecast

Addex Therapeutics Ltd (ADXN) July 20, 2021 Stock Price, Analysis & Forecast

Addex Therapeutics Ltd (NASDAQ: ADXN) opened the trading session on July 20, 2021, at $9.48, showing a change of -2.7594% VS the previous close at $9.35. During the trading session, the stock price increased to $9.52 and declined to $9.09. Finally, the stock stabilized at $9.09. But still, bearing in mind a longer-term approach, Addex Therapeutics Ltd reported a 52 Week Range within the framework of $7-$17.98.

Addex Therapeutics Ltd's shares outstanding currently worth $7.26M, in addition to a float of $3.35M. ADXN operates in the LIFE SCIENCES sector of the PHARMACEUTICAL PREPARATIONS industry and has a market capitalization of $66.03M (as of July 20, 2021). It's worth noting that Addex Therapeutics Ltd's 50-day Moving Average stabilized at $10.09, while such sign as 200-day Moving Average is at the moment $10.59.

To evaluate the company's efficiency, let's take note of Addex Therapeutics Ltd's conglomerate performance. To date, ADXN has full-time employees. Addex Therapeutics Ltd has generated $inf per worker During the last fiscal year. In the interim, ADXN's income per employee was $inf. And now, let's take note of the company's income report. Addex Therapeutics Ltd's Net Income for the last fiscal year was $-12,858,599, while such sign as Income Before Taxes was at the level of $-12,858,599. ADXN's Operating Income was at the mark of $-12,243,057.

Addex Therapeutics Ltd (ADXN) Earnings & Revenue

Talking about the Profitability, ADXN reached a Profit Margin of -290.8% and an Operating Margin (TTM) of -288.9%. However, when we touch the questions of management effectiveness, Addex Therapeutics Ltd generated a Return on Equity (TTM) of -52.7% and a Return on Assets (TTM) of -24.9%. A bit more income statements might bring clarity to our overview. According to the results of the latest quarter ended March 31, 2021, Addex Therapeutics Ltd generated Revenue (TTM) of $3.85M, reporting a Quarterly Revenue Growth of -3.2%. As for the Revenue Per Share (TTM), this indicator was at the mark of $0.81. The company's Gross Profit (TTM) was $-6,470,057, while according to the EBITDA report, it was estimated at $.

Addex Therapeutics Ltd (NASDAQ: ADXN) Owners & Shares

Finally, let's take a look at the share statistics. As mentioned above, ADXN's shares outstanding now amounts to $7.26M, where Shares Short was $198 versus the prior month amounted to $4,951. (Short % of Float was 0.01%). And now, let's overview which kind of investors works with Addex Therapeutics Ltd's stocks. ADXN's current ownership accounts for 3.855% institutional investors, while 0% of shares belong to the insiders. Also worth mentioning some indicators affecting dividends & splits. Thus, ADXN's Forward Annual Dividend Rate is currently at the mark of 0, whereas the Dividend Yield is 0%, and a Dividend Payout Ratio is 0% (Dividend Date: December 31, 1969). The company's Dividend Per Share sign thereby is $None.

ADXN Trading Performance

It's time to observe the current performance indicators for Addex Therapeutics Ltd. ADXN's price/earnings to growth ratio during the last reported quarter was 0%. The company's PE Ratio stands at None%, while ADXN's Beta score is 1.421. Also worth noting that Addex Therapeutics Ltd's Diluted EPS (Earnings per Share) trailing twelve months is at the mark of -2.574. Other valuable indicators are Price To Sales Ratio (TTM), which is currently recorded at 11.08, as well as Price To Book Ratio, which amounts to 2.28.

Addex Therapeutics Ltd Analysis & Estimates

Within the previous 9-day period, Addex Therapeutics Ltd's Average True Range (ATR) was 0.5359, while the stock's Stochastic SlowD moving average was 20.1599%, and the SlowK moving average volumed at 20.1599%.

You may also like: